Joseph Tripodi, MD
Vascular Surgery · Middlebury, CTNPI 1386628964
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 28 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 46.6% of the total. Reporting peaked in 2024 at $418 and has fallen 70.4% since, to $123 in 2025. That places this record below the midpoint for vascular surgery clinicians in CT, where the typical reported total is $7,252.
Across 28 payments — averaging $34.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$446
- Biohaven Pharmaceuticals, Inc.$167
- Amgen$66
- Novo Nordisk$62
- Bayer$57
- Biohaven Pharmaceutical Holding Company Ltd.$49
- plus $108 from 4 others
What the payments were for
- Food & beverage$94299%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $446 |
| Biohaven Pharmaceuticals, Inc. | 4 | $167 |
| Amgen | 4 | $66 |
| Novo Nordisk | 3 | $62 |
| Bayer | 2 | $57 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $49 |
| QOL Medical, LLC | 2 | $36 |
| AbbVie | 2 | $31 |
| GSK | 2 | $27 |
| Corcept Therapeutics | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$255
- BREZTRI$123
- NURTEC ODT$116
How this compares
$956 in reported general payments places this provider in the 10th percentile of 82 vascular surgery providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PercocetOxycodone Hcl/Acetaminophen | 15 | $20,693 |
| Oxycodone Hcl | 137 | $1,382 |
| Furosemide | 21 | $34 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $6 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Middlebury
- Uwe FischerNew London$941K
- Paul GagneDarien$766K
- Naiem NassiriNew Haven$348K
- Lee GoldsteinStratford$272K
- Mohiuddin CheemaHartford$228K
- Bauer SumpioNew Haven$205K
- Javairiah FatimaDanbury$152K
- Bart MuhsOld Saybrook$66K
- Jonathan BowmanDarien$53K
- Maria LitzendorfManchester$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.